ホーム › トリプルネガティブ乳がん › ミズーリ州
ミズーリ州におけるトリプルネガティブ乳がんの臨床試験
ミズーリ州内の拠点で、トリプルネガティブ乳がんに関する24件の研究が参加者を募集しています。
ミズーリ州内の都市
公式研究テキスト（英語）
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Washington University School of Medicine in St. Louis, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Washington University Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- Washington University, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06799065A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
- Washington University Siteman Cancer Center ( Site 0031), St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Washington University, St Louis
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Lake Regional Hospital ( Site 0009), Osage Beach
- Siteman Cancer Center ( Site 0099), St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Local Institution - 0140, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Washington University, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Washington University School of Medicine, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT03606967Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Oncology Hematology Associates, Springfield
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Washington University, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07115043A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- 他2件
被験者募集中観察研究健康なボランティア歓迎
全年齢 · 全性別 · 2026/08/18更新 · NCT02302742A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Saint Luke's Cancer Institute, Kansas City
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Washington University School of Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/13更新 · NCT07137416Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - SPG, Springfield
- Mercy Hospital - South, St Louis
- Mercy Hospital -STL, St Louis
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/29更新 · NCT07327489A Study of LY4175408 in Participants With Advanced Cancer
- Washington University, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT07046923Study of XB010 in Subjects With Solid Tumors
- Siteman Cancer Center, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/22更新 · NCT06545331A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Siteman Cancer Center, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/30更新 · NCT06926920JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Washington University, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/09更新 · NCT05490472A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Washington University, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/09/09更新 · NCT06682793A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- Cox Medical Center, Springfield
被験者募集中第3相
18歳〜65歳 · 女性 · 2025/03/21更新 · NCT03671044ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。